Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Mun Yee Koh, Tae-Hoon Chung, Nicole Xin Ning Tang, Sabrina Hui Min Toh, Jianbiao Zhou, Tze King Tan, Leilei Chen, Wee Joo Chng, Phaik Ju Teoh

Blood blood.2024024429.

https://doi.org/10.1182/blood.2024024429

Published: 2024

Includes: Supplemental data

Journal Articles

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

Phaik Ju Teoh, Ricardo De Matos Simoes, Tae-Hoon Chung, Torsten Steinbrunn, Lisa B Leypoldt, Olga Dashevsky, Francisca Vazquez, Wee-Joo Chng, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 3293.

https://doi.org/10.1182/blood-2023-190050

Published: 2023

Journal Articles

Systematic Functional Characterization for Loss of Function Events Cooperating with TP53 Loss in High-Risk 17p13(del) Multiple Myeloma

Phaik Ju Teoh, Ricardo De Matos Simoes, Tae-Hoon Chung, Mick Lee, Olga Dashevsky, Shizuka Yamano, Roger Foo, Wee Joo Chng, Constantine S. Mitsiades

Blood (2022) 140 (Supplement 1): 7110–7111.

https://doi.org/10.1182/blood-2022-159316

Published: 2022

Journal Articles

Elucidating the Role of ADAR1 in Regulating Immunotherapeutic Response in Multiple Myeloma

Mun Yee Koh, Phaik Ju Teoh, Tae-Hoon Chung, Leilei Chen, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 7084–7085.

https://doi.org/10.1182/blood-2022-158848

Published: 2022

Journal Articles

Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma

Sinan Xiong, Jianbiao Zhou, Tze King Tan, Sabrina Hui-Min Toh, Kalpnaa Balan, Yunlu Jia, Tae-Hoon Chung, Takaomi Sanda, Wee Joo Chng

Blood (2021) 138 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2021-149006

Published: 2021

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Katja Weisel, MD, George F. Geils, MD, Lionel Karlin, MD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Tae-Hoon Chung, Chang-Ki Min, MD PhD, Kazutaka Sunami, MD PhD, Amanda Goldrick, MD, Belle Fang, Jessica Fowler, PhD, Maria-Victoria Mateos, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133908

Published: 2020

Journal Articles

Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients

Cinnie Yentia Soekojo, MD, Tae-Hoon Chung, Muhammad Shaheryar Furqan, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136553

Published: 2020

Journal Articles

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma

Boheng Li, Junli Yan, The Phyu, Shuangyi Fan, Tae-Hoon Chung, Nurulhuda Mustafa, Baohong Lin, Lingzhi Wang, Pieter Johan Adam Eichhorn, Boon-Cher Goh, Siok-Bian Ng, Dennis Kappei, Wee-Joo Chng

Blood (2019) 134 (23): 2046–2058.

https://doi.org/10.1182/blood.2019000381

Published: 2019

Includes: Supplemental data

Journal Articles

Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma

Jianbiao Zhou, MD PhD, Yunlu Jia, MD, Tze King Tan, PhD, Tae-Hoon Chung, PhD, Takaomi Sanda, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2019) 134 (Supplement_1): 362.

https://doi.org/10.1182/blood-2019-124252

Published: 2019

Journal Articles

Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma

Phaik Ju Teoh, PhD, Tae-Hoon Chung, Leilei Chen, PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 4513.

https://doi.org/10.1182/blood-2018-99-118895

Published: 2018

Journal Articles

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

Phaik Ju Teoh, Omer An, Tae-Hoon Chung, Jing Yuan Chooi, Sabrina H. M. Toh, Shuangyi Fan, Wilson Wang, Bryan T. H. Koh, Melissa J. Fullwood, Melissa G. Ooi, Sanjay de Mel, Cinnie Y. Soekojo, Leilei Chen, Siok Bian Ng, Henry Yang, Wee Joo Chng

Blood (2018) 132 (12): 1304–1317.

https://doi.org/10.1182/blood-2018-02-832576

Published: 2018

Includes: Supplemental data

Journal Articles

JMJD3 Is a Potential Tumor Suppressor Gene That Cooperates with TP53 in Chromosome 17p13

Phaik Ju Teoh, PhD, Tae-Hoon Chung, Chirackal Sintosebastian, Rafael Fonseca, MD, Wee Joo Chng, MB ChB, MRCP, PhD

Blood (2017) 130 (Supplement 1): 1761.

https://doi.org/10.1182/blood.V130.Suppl_1.1761.1761

Published: 2017

Journal Articles

Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL)

Boheng Li, Junli Yan, PhD, Tae-Hoon Chung, PhD, Pei Tsung Lee, Wee Joo Chng, MD PhD

Blood (2016) 128 (22): 1773.

https://doi.org/10.1182/blood.V128.22.1773.1773

Published: 2016

Journal Articles

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma

Junli Yan, Boheng Li, Baohong Lin, Pei Tsung Lee, Tae-Hoon Chung, Joy Tan, Chonglei Bi, Xue Ting Lee, Viknesvaran Selvarajan, Siok-Bian Ng, Henry Yang, Qiang Yu, Wee-Joo Chng

Blood (2016) 128 (7): 948–958.

https://doi.org/10.1182/blood-2016-01-690701

Published: 2016

Includes: Supplemental data

Journal Articles

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Changhong Yin, MS, Tae-Hoon Chung, PhD, Janet Ayello, MS, MT(ASCP), Tae-Hyun Park, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD, Sanghoon Lee, Ph.D, MSc.

Blood (2013) 122 (21): 3852.

https://doi.org/10.1182/blood.V122.21.3852.3852

Published: 2013

Journal Articles

A Novel Measure of Chromosome Instability Is An Independent Prognostic Factor in Multiple Myeloma

Tae-Hoon Chung, PhD, Rafael Fonseca, MD, Wee-Joo Chng, M.B.Ch.B

Blood (2011) 118 (21): 1824.

https://doi.org/10.1182/blood.V118.21.1824.1824

Published: 2011

Journal Articles

Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).

Wee J. Chng, MD, Tae-Hoon Chung, PhD, Jonathan J. Keats, PhD, Angela Baker, PhD, P. Leif Bergsagel, MD, John Carpten, PhD, Rafael Fonseca, MD

Blood (2007) 110 (11): 2471.

https://doi.org/10.1182/blood.V110.11.2471.2471

Published: 2007

Journal Articles

Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma.

Wee-Joo Chng, MD, Angela Baker, PhD, Travis Henry, PhD, Tammy Price-Troska, Scott Van Wier, Tae-Hoon Chung, PhD, Kim Henderson, Gregory Ahmann, Martha Lacy, MD, Angela Dispenzieri, MD, Morie Abraham Gertz, MD, Philip Greipp, MD, Peter Leif Bergsagel, MD, John Carpten, PhD, Rafael Fonseca, MD

Blood (2006) 108 (11): 113.

https://doi.org/10.1182/blood.V108.11.113.113

Published: 2006

Journal Articles

High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.

Blood (2006) 108 (11): 3407.

https://doi.org/10.1182/blood.V108.11.3407.3407

Published: 2006

Journal Articles

A Comparative Analysis of Chromosome 13 Gene Expression and Copy Number Changes in Multiple Myeloma Using Array-Based Methods.

Blood (2005) 106 (11): 1557.

https://doi.org/10.1182/blood.V106.11.1557.1557

Published: 2005

NARROW

ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

Systematic Functional Characterization for Loss of Function Events Cooperating with TP53 Loss in High-Risk 17p13(del) Multiple Myeloma

Elucidating the Role of ADAR1 in Regulating Immunotherapeutic Response in Multiple Myeloma

Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma

Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma

Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

JMJD3 Is a Potential Tumor Suppressor Gene That Cooperates with TP53 in Chromosome 17p13

Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL)

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

A Novel Measure of Chromosome Instability Is An Independent Prognostic Factor in Multiple Myeloma

Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).

Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma.

High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.

A Comparative Analysis of Chromosome 13 Gene Expression and Copy Number Changes in Multiple Myeloma Using Array-Based Methods.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only